Clinical Trials in Sutton - 19 Recruiting Industry Studies

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca · started 2020-08-18

📍 London · Manchester · Sutton

NCT04482309 on ClinicalTrials.gov ↗

Active Phase 1

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Metastatic Neuroendocrine Prostate Cancer
Novartis Pharmaceuticals · started 2024-07-29

📍 Sutton · London

NCT06379217 on ClinicalTrials.gov ↗

Recruiting Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

KRAS Altered Advanced or Metastatic Solid Tumors
Amgen · started 2025-07-31

📍 London · Sutton

NCT07094113 on ClinicalTrials.gov ↗

Recruiting Phase 1

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

Advanced Solid Tumors
AstraZeneca · started 2025-11-25

📍 Newcastle upon Tyne · Sutton

NCT07161414 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

HER2-positive Breast Cancer
Hoffmann-La Roche · started 2026-05-21

📍 Leicester · London · Manchester · Sutton

NCT07413939 on ClinicalTrials.gov ↗

Recruiting Phase 2

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
AbbVie · started 2025-04-24

📍 Sutton

NCT06820463 on ClinicalTrials.gov ↗

Active Phase 3

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer · started 2014-12-17

📍 Glasgow · Wonford · London · Sutton · Birmingham

NCT02319837 on ClinicalTrials.gov ↗

Recruiting Phase 3

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca · started 2026-05-05

📍 Edinburgh · Hampshire · Leeds · London · Manchester

NCT07509151 on ClinicalTrials.gov ↗

Recruiting Phase 3

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Non-small Cell Lung Cancer
Boehringer Ingelheim · started 2026-01-16

📍 Cardiff · Edinburgh · London · Manchester · Sutton

NCT07195695 on ClinicalTrials.gov ↗

Recruiting Phase 1

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer
ORIC Pharmaceuticals · started 2022-06-01

📍 Sutton

NCT05413421 on ClinicalTrials.gov ↗

Recruiting Phase 1/Phase 2

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
BeOne Medicines · started 2021-09-16

📍 Headington · London · Sutton · Truro

NCT04973605 on ClinicalTrials.gov ↗

Active Phase 1

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Neoplasm Metastasis, Non-Small Cell Lung Cancer
Boehringer Ingelheim · started 2021-07-02

📍 London · Sutton

NCT04886804 on ClinicalTrials.gov ↗

Recruiting Phase 1/Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim · started 2024-06-03

📍 Cardiff · Leeds · London · Manchester · Newcastle upon Tyne

NCT06324357 on ClinicalTrials.gov ↗

Recruiting Phase 1

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd · started 2026-07

📍 Cambridge · Edinburgh · Glasgow · Leeds · Leicester

NCT07665515 on ClinicalTrials.gov ↗

No trials match your search.

Browse by city

London · 118 Manchester · 30 Glasgow · 27 Cambridge · 27 Birmingham · 24 Leicester · 23 Bristol · 23 Leeds · 22 Sutton · 19 Oxford · 19 Liverpool · 18 Edinburgh · 15 Nottingham · 14 Cardiff · 14 Newcastle upon Tyne · 13 Sheffield · 12

Browse by condition

Obesity · 5 Chronic Lymphocytic Leukemia · 5 Cancer · 4 Breast Neoplasms · 3 Non-small Cell Lung Cancer · 3 Small Lymphocytic Lymphoma · 3 Multiple Myeloma · 3 Hypertension · 3 Heart Failure · 3 Triple Negative Breast Neoplasms · 2 Lymphoma, Non-Hodgkin · 2 Lymphoma, Follicular · 2 Lymphoma, Large B-Cell, Diffuse · 2 Gastric Cancer · 2 Metastatic Prostate Cancer · 2 Overweight · 2

Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk/city/sutton (Accessed: 11 July 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.